| 前收市價 | 5.50 |
| 開市 | 無 |
| 買盤 | 5.70 |
| 賣出價 | 6.10 |
| 拍板 | 10.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 5.50 - 5.50 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
ZacksIs Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
ZacksAnnexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
ZacksWall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
